- 中文名稱
Anti-Human Thrombopoietin
- 英文名字
- Anti-Human Thrombopoietin
- 供應(yīng)商
- ReliaTech
- 產(chǎn)品貨號
- 101-M647
- 產(chǎn)品報價
- ¥詢價/100ug

- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購買方式
- 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金,在線支付寶及網(wǎng)銀支付,或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞

- 背景資料
- Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders. The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80 - 85 kDa protein that consists of an N-terminal domain with homology to Erythropoietin (Epo) and a C-terminal domain that contains multiple N-linked and O-linked glycosylation sites. Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C-terminal substitutions. Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors. Several other cytokines can promote these functions as well but only in cooperation with Tpo. Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage. Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation. It is cleaved by platelet-derived thrombin following Arg191 within the C-terminal domain and subsequently at other sites upon extended digestion.
- 應(yīng)用類型
- WB
- 免疫原
- 該Anti-Human Thrombopoietin的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 來源宿主
- 該Anti-Human Thrombopoietin的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 反應(yīng)性
- 該Anti-Human Thrombopoietin的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 保存建議
- 該Anti-Human Thrombopoietin的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議:Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH),1999年成立,總部位于德國不倫瑞克,是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外,ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品,產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。

- 注意
-
該頁面的中文產(chǎn)品信息的翻譯,僅供參考。準(zhǔn)確的產(chǎn)品信息請以廠家的英文說明書為準(zhǔn)。下單前,請瀏覽說明書確認(rèn)。
-